The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD)

Jonathan I. Silverberg,1 Brian Feinstein,2 Emma Guttman-Yassky,3 Eric Simpson,4 Bruce Strober5,6 Jinhua Xu,7,8 Pauline Li,9 Jing Song,9 Malinda Longphe,9 Paul Smith,9 Zheng Wei,9 Selwyn Ho9

1Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA; 2Encore Medical Research LLC, FL, USA; 3Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; 4Department of Dermatology, Oregon Health and Science University, Portland, OR, USA; 5Yale University, New Haven, CT, USA; 6Central Connecticut Dermatology, Cromwell, CT, USA; 7Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. 8Shanghai Institute of Dermatology, Shanghai, China; 9Connect Biopharma, San Diego, CA, USA and Suzhou, China.

Introduction: CBP-201 is a novel monoclonal antibody targeting IL-4Ra. A Phase 2b trial (WW001) in moderate-to-severe patients with AD successfully met its primary and key secondary endpoints, despite the trial recruiting less severe AD patients than phase 3 trials of the approved IL-4Ra agent during the ongoing COVID-19 pandemic (Strober et al, Maui Derm 2022). As such, post-hoc analyses were conducted to determine the relationship between baseline levels of thymus- and activation-regulated chemokine (TARC), a chemokine distinctively expressed on Th2 lymphocytes and a biomarker that correlates with AD disease activity, and efficacy outcomes.

Methods: In this double-blind, placebo-controlled, international trial (NCT04444752), with 16-week treatment and 8-week follow-up periods, 226 adults with moderate-to-severe AD were randomized (1:1:1:1) to subcutaneous CBP-201 (300mg Q2W, 150mg Q2W, 300mg Q4W) or placebo. The overall trial population was stratified into three subgroups according to baseline TARC; “low” (≤116.74 pg/ml), “mid” (>116.74 to ≤291 pg/ml), “high” (>291 pg/ml) and the relationship with disease severity and effect on other biomarkers and efficacy outcomes was determined.

Results: Each subgroup included 74 patients. The “high” subgroup had higher baseline EASI (median 27.8) compared with either the “low” (median EASI, 18.4) or “mid” (median EASI, 19.9) subgroups.

Across all CBP-201 doses, Week 16 clinical responses were greatest in the “high” subgroup with numerically larger absolute reductions in EASI scores compared to the “low” subgroup (300 mg Q4W: “high” -25 vs “low” -12; 300 mg Q2W: -20 vs -11; 150 mg Q2W: -20 vs -10 respectively). Similar Week 16 trends were noted for placebo-adjusted LS mean percent EASI reductions (-54% vs -19%; -33% vs -18%; -35% vs -11%), absolute reductions in PP-NRS (-4.3 vs -2.4; -4.0 vs -3.4; -3.2 vs -2.5) and percent PP-NRS change (-24% vs +8.3%; -19% vs -16%; -8.1% vs +2.8%).

When comparing baseline EASI tertiles, clinical response was also greater in the most severe (EASI ≥26.4) vs least severe (EASI ≤18.4) subgroup as expected from the correlation between baseline TARC and baseline EASI.
Mean TARC levels themselves were unchanged from baseline at Week 16 for the “low” subgroup but decreased by 54–76% across the treatment arms in the “high” subgroup. IgE levels showed a greater reduction in the “high” vs the “low” subgroup.

Patients randomized in China (N=32) had both higher baseline TARC levels (median 457.6 pg/mL) and EASI scores (median 26.9) and experienced greater clinical responses compared with the overall trial population (Strober et al, Maui Derm 2022), consistent with the effects seen in the high TARC group of the whole population.

**Conclusion:** This post-hoc analysis of the Phase 2b trial of CBP-201 in patients with moderate-to-severe AD, showed that higher baseline TARC levels correlated with higher baseline EASI and that CBP-201 in patients with higher baseline TARC achieved greater placebo adjusted clinical responses. These results highlight the relationship of baseline disease characteristics on efficacy outcomes and the difficulties in making comparisons across trials and patients with distinct immunology and baseline severity.

**Funding:** Connect Biopharma.

Jonathan I. Silverberg,1 Brian Feinstein,2 Emma Guttman-Yassky,3 Eric Simpson,4 Bruce Strober5,6, Jinhua Xu,7,8 Pauline Li,9 Jing Song,9 Malinda Longphre,9 Paul Smith,9 Zheng Wei,9 Selwyn Ho9

**Financial disclosures**

**JIS:**
- **Stock ownership:** AbbVie, Arcutis, Eli Lilly
- **Consultant (honoraria):** AbbVie, Afxys, Aobiome, Arena Pharmaceuticals, Asana, Aslan, BioMX, Bluefin, Bodewell, Boehringer Ingelheim, Celgene, Connect Biopharma, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi-Genzyme
- **Research grants:** Galderma, Pfizer

**EGY:**
- **Consultant (honoraria):** AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, DBV, DS Biopharma, Eli Lilly, EMD Serono, Galderma, Ichnos Sciences (Glenmark), Incyte, Janssen Biotech, Kyowa, Kirin, Leo Pharmaceuticals, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, UCB, Union Therapeutics, Connect, Biopharm, SATO, Siolta Therapeutics, Target Pharma Solutions, Ventyx, Novartis, Boston Pharmaceuticals, Evidera, Principia, Bluefin Biomedicine
- **Investigator:** AbbVie, AstraZeneca, Eli Lilly, Kyowa Kirin, Leo Pharmaceuticals, Pfizer, Regeneron
**Advisory Boards:** AbbVie, Aditum Bio, Aena Pharmaceuticals, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, DBV, Eli Lilly, Galderma, Ichnos Sciences (Glenmark), Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharmaceuticals, Pfizer, RAPT Therapeutics (Fix Bio), Regeneron, Sanofi, Union Therapeutics, Connect Biopharma, SATO, S iota Therapeutics, Target Pharma Solutions, Ventyx, Novartis, Bluefin Biomedicine.

**Research Grants:** Almirall, Amgen, AnaptysBio, Asana Bioscience, AstraZeneca, Bristol Meyers Squibb, Cara Therapeutics, DS Biopharma, Galderma, Innovaderm, Janssen Biotech, Kiniska, Kyowa Kirin, Leo Pharmaceuticals, Pfizer, Regeneron, UCB, and KAO

**Stockholder:** RAPT

**Personal fees:** AbbVie, Amgen, Arena Pharmaceuticals, Aslan Pharma, Boston Consulting Group, Collective Acumen, LLC (CA), Dermira, Eli Lilly, Evidera, ExcerptaMedica, Forte Bio RX, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin Pharmaceutical Development, Leo Pharma, Medscape LLC, Pfizer, Physicians World LLC, Regeneron, Sanofi-Genzyme, Trevi therapeutics, WebMD. *These potential conflicts of interest have been reviewed and managed by OHSU.*

**Grants (or Principal investigator role):** AbbVie, Amgen, Arcutis, Aslan, Corevita, Dermira, Eli Lilly, Incyte, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and TARGET-DERM. *These potential conflicts of interest have been reviewed and managed by OHSU.*

**Consultant (honoraria):** AbbVie, Almirall, Amgen, Arcutis, Arena, Arista, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo Pharma, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics

**Stock Options:** Connect Biopharma, Mindera Health

**Speaker:** AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme

**Scientific Co-Director (consulting fee):** CorEvitas (formerly Corrona) Psoriasis Registry

**Investigator:** Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis

**Editor-in-Chief (honorarium):** Journal of Psoriasis and Psoriatic Arthritis

**BF, JX:** No financial disclosures

JX, PL, JS, ML, PS, ZW and SH are employees of Connect Biopharma.
Keywords
Atopic dermatitis, IL-4, CBP-201, biologics, monoclonal antibody, phase 2, efficacy, biomarker